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It is now more than 25 years since the National Institute 
of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders 
Association (now the Alzheimer’s Association) estab-
lished the most commonly used diagnostic criteria for 
Alzheimer’s disease (AD) [1]. Th   ese criteria require that 
the patient is demented before a diagnosis of AD can be 
made. We now know, however, that dementia represents 
a late stage of AD and that AD-speciﬁ  c neuro  degenera-
tion starts many years earlier. Disease-modify  ing drugs 
that attack primary pathogenic processes underlying AD 
will probably be most eﬀ  ective in the earlier stages of the 
disease, before plaque and tangle load and neuro-
degeneration have become too severe.
If we want to do something substantial about the 
prospects of AD patients in the near future, we need to 
develop diagnostic algorithms that recognize pre-
dementia stages of the disease. Th   is has become possible 
thanks to brain imaging and cerebrospinal ﬂ  uid (CSF) 
analyses that predict AD with dementia in patients with 
mild cognitive impairment [2-4]. Accordingly, new 
research criteria for the diagnosis have been proposed 
that capture both the prodromal and the more advanced 
dementia stages of the disease in the same diagnostic 
framework [5]. In the present article, we discuss what is 
needed before this type of criteria can be implemented in 
the clinical routine diagnostic work-up of patients with 
cognitive disturbances.
Validated biomarkers for Alzheimer’s disease
CSF levels of total tau reﬂ  ect cortical axonal degenera-
tion, levels of phospho-tau reﬂ  ect tangle pathology and 
levels of the 42-amino-acid isoform of amyloid β (Aβ42) 
reﬂ  ect brain amyloid pathology [2]. Magnetic resonance 
imaging (MRI) of hippocampal atrophy gauges progres-
sion of the neuro  degeneration in a manner that correlates 
well with both neuropathological measures of tangle load 
and cognitive symptoms [3]. 2[18F]-Fluoro-2-deoxy-d-
glucose positron emission tomography (FDG-PET) allows 
for the assess  ment of the glucose metabolism rate in 
speciﬁ  c brain regions and can detect metabolic dysfunc-
tions in brain regions aﬀ  ected by AD also in pre-dementia 
stages [4]. Amyloid plaques in the living human brain can 
be visualized using amyloid-binding PET tracers such as 
Pittsburgh Compound B (PIB) [4]. Marked PIB retention 
is found in AD patients in areas of the brain known to 
contain large amounts of Aβ plaques.
When do the biomarkers turn positive?
In a recent review, Jack and coworkers condense the AD 
biomarker literature to model the sequence of patho-
logical events in AD [6]. Th  e ﬁ  rst biomarker change to 
occur in AD is probably the lowering of the CSF Aβ42, 
reﬂ  ecting the formation of oligomers and loose aggre-
gates of Aβ in the brain. Th   is change is followed by PIB-
PET positivity as a sign of accumulation of ﬁ  brillar Aβ in 
the brain. Aβ oligomerization, or an unknown molecular 
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glucose metabolism on FDG-PET – and axonal 
degeneration and hyperphosphorylation of tau – seen as 
elevations in total tau and phospho-tau concentrations in 
the CSF. Eventually, the axonal and neuronal loss in 
speciﬁ   c brain regions is manifested as reduced MRI 
volumes of, for example, the hippocampus, which 
parallels cognitive decline. Th   e model is supported by a 
vast body of literature and suggests that most biomarkers 
listed above are positive in the mild cognitive impairment 
stage of AD and that amyloid-related biomarkers are the 
most promising antecedent biomarkers for AD [6].
What is the diagnostic performance of these 
biomarkers?
Sensitivity and speciﬁ  city ﬁ  gures for the diﬀ  erent bio-
markers vary between studies but tend to be above 80% 
for distinguishing AD patients from cognitive normal 
controls and for identifying incipient AD in the mild 
cognitive impairment stage of the disease, at least in 
standardized monocenter studies [2-4]. Only a few of the 
biomarkers have as yet undergone testing in large 
multicenter settings.
Why are Alzheimer’s disease biomarkers not 100% 
specifi  c?
Currently available biomarkers do not show full-proof 
diagnostic accuracy. Except for technical shortcomings 
with the biomarkers, however, there are several funda-
mental reasons why 100% sensitive and speciﬁ  c  bio-
markers for AD are an unreachable goal. Most biomarker 
studies are based on clinically diagnosed cases, which 
introduces a relatively large percentage of misdiagnosis 
[7]. Th   ere is also a large overlap in pathology between AD 
and other dementias, such as Lewy body dementia and 
vascular dementia [8,9]. Th   is overlap in pathology 
essentially precludes the possibility of ﬁ  nding biomarkers 
that have close to 100% sensitivity and speciﬁ  city for AD. 
One way out of this conundrum might be to reconsider 
the terminology. Perhaps we should stop using the term 
AD biomarkers and instead acknowledge that the 
biomarkers reﬂ   ect distinct pathogenic or pathologic 
processes; for example, amyloid retention in the brain 
and degeneration of nonmyelinated cortical axons. Th  ese 
changes, especially in combination, are frequently seen in 
AD but may also be present in other neurodegenerative 
disorders, especially in isolation.
It is known that a signiﬁ   cant percentage of non-
demented older people have enough plaques and tangles 
to warrant a neuropathological diagnosis of AD [10]. 
Recent biomarker studies corroborate this ﬁ  nding. For 
example, a relatively large portion of cognitively normal 
older people have CSF Aβ42 values or PIB-PET binding 
similar to that found in AD cases [2-4]. Th  ese ﬁ  ndings 
raise the question of whether the term normal aging has 
to be redeﬁ  ned. Longitudinal studies will tell us whether 
these individuals do have preclinical AD, or whether 
silent AD pathology is part of the normal aging process.
Which biomarkers should be used and how?
More detailed guidelines on how biomarkers should be 
implemented in the diagnostic procedure for early AD 
are needed for them to be used in clinical routine. 
Notably, these guidelines have to be down-to-earth to 
allow for general implementation. A large number of 
unresolved issues need to be settled.
Assessment of memory
Th   ere is to date no consensus on which tests should be 
used to identify impairment in episodic memory and 
other cognitive domains beyond what is expected due to 
normal aging [11]. Further, a major challenge will be to 
determine cut-oﬀ   points that can be generally applied to 
identify patients with cognitive dysfunction, since a cut-
oﬀ   point set in one population does not necessarily apply 
to populations with other ethnic or socioeconomic 
characteristics.
Biochemical markers in the cerebrospinal fl  uid
Although assays for measurement of tau and Aβ in CSF 
have been well validated and the biological variability for 
these biomarkers is low [2], there is a variation in bio-
marker levels in reports from diﬀ  erent research centers, 
even when using the same assay [12]. Moreover, there is 
no accepted gold standard method and no consensus on 
what assays are to be used. A ﬁ  rst study comparing CSF 
biomarker levels between laboratories found excellent 
within-laboratory variation, but a large variation between 
centers [13]. Similar results were reported in a large 
multicenter study [14]. Th   is variation complicates 
multicenter research studies and trials, and also precludes 
the introduction of generally applicable cut-oﬀ   levels. To 
help deal with this problem, a global quality control 
program for CSF biomarkers was recently launched [12].
Structural magnetic resonance imaging
Th  e utility of structural imaging in diagnostic guidelines 
will be increased by standardization of acquisition and 
analysis methods [3]. Which is the region of interest with 
regards to AD-type brain atrophy measured on MRI? 
Which methods and what cut-oﬀ   points should be used to 
distinguish age-related brain atrophy from atrophy in AD?
Positron emission tomography
Similar standardization issues that apply to MRI also 
apply to PET imaging of cerebral Aβ aggregation and 
glucose metabolism. Where in the brain should amyloid 
retention be quantiﬁ  ed using amyloid PET? Which of the 
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used? Where in the brain should we monitor cerebral 
glucose metabolism using FDG-PET, and should we 
focus on diﬀ  erent regions in diﬀ  erent disease stages?
How about availability and costs?
For the implementation of these biomarkers in a 
diagnostic algorithm, availability and ﬁ  nancial considera-
tions may be of importance. Amyloid PET is at present 
only available in highly specialized centers. In Sweden, 
the approximate cost is $200 for CSF biomarkers 
(combined analysis of total tau, phospho-tau and Aβ42), 
$500 for structural MRI and $5,000 for amyloid PET – 
ﬁ  gures that probably vary considerably between countries.
How should we move forward?
Th   ere is an enormous amount of literature showing good 
or excellent diagnostic performance of several biomarkers 
reﬂ  ecting diﬀ  erent facets of the disease process in AD. 
We have unprecedented possibilities to phenotype our 
patients. We think the time is ripe to boldly develop the 
biomarker-based research criteria proposed by Dubois 
and coworkers [5] into a detailed, practical and feasible 
diagnostic algorithm that will be applicable in clinics 
worldwide. It is easy to predict that this will be a challeng-
ing process. Th  e proposed algorithm would require 
evaluation in a longitudinal clinical multicenter study of 
patients with memory problems to assess its diagnostic 
(or strictly speaking as it is now, predictive) accuracy 
against postconversion clinical dementia diagnoses and, 
whenever possible, to neuropathological ﬁ  ndings before 
general implementation in the clinic. Such an evaluation 
will require some signiﬁ  cant period of time. It is in the 
best interest of all who wish to develop better therapeutic 
paradigms for this devastating disease that this process 
be started now.
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